Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited Fundamental Analysis
Dr. Reddy's Laboratories Limited (RDY) shows moderate financial fundamentals with a PE ratio of 25.43, profit margin of 12.72%, and ROE of 11.83%. The company generates $336.2B in annual revenue with strong year-over-year growth of 16.61%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 79.9/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze RDY's fundamental strength across five key dimensions:
Efficiency Score
WeakRDY struggles to generate sufficient returns from assets.
Valuation Score
ModerateRDY shows balanced valuation metrics.
Growth Score
ModerateRDY shows steady but slowing expansion.
Financial Health Score
ExcellentRDY maintains a strong and stable balance sheet.
Profitability Score
WeakRDY struggles to sustain strong margins.
Key Financial Metrics
Is RDY Expensive or Cheap?
P/E Ratio
RDY trades at 25.43 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, RDY's PEG of -0.01 indicates potential undervaluation.
Price to Book
The market values Dr. Reddy's Laboratories Limited at 2.95 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 13.76 times EBITDA. This signals the market has high growth expectations.
How Well Does RDY Make Money?
Net Profit Margin
For every $100 in sales, Dr. Reddy's Laboratories Limited keeps $12.72 as profit after all expenses.
Operating Margin
Core operations generate 14.74 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $11.83 in profit for every $100 of shareholder equity.
ROA
Dr. Reddy's Laboratories Limited generates $7.55 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Dr. Reddy's Laboratories Limited produces operating cash flow of $56.40B, showing steady but balanced cash generation.
Free Cash Flow
Dr. Reddy's Laboratories Limited produces free cash flow of $24.19B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $29.06 in free cash annually.
FCF Yield
RDY converts 2.23% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
25.43
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.01
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.95
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.23
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.21
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.80
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.12
vs 25 benchmark
ROA
Return on assets percentage
0.08
vs 25 benchmark
ROCE
Return on capital employed
0.12
vs 25 benchmark
How RDY Stacks Against Its Sector Peers
| Metric | RDY Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 25.43 | 28.62 | Better (Cheaper) |
| ROE | 11.83% | 783.00% | Weak |
| Net Margin | 12.72% | -48181.00% (disorted) | Strong |
| Debt/Equity | 0.21 | 0.39 | Strong (Low Leverage) |
| Current Ratio | 1.80 | 4.12 | Neutral |
| ROA | 7.55% | -21914.00% (disorted) | Weak |
RDY outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Dr. Reddy's Laboratories Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
85.59%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
188.67%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
54.87%
Industry Style: Defensive, Growth, Innovation
High Growth